Clarithromycin IV is Not Available in the United States
Clarithromycin does not have an FDA-approved intravenous formulation in the United States, which is why you cannot find it listed as an IV option in Sanford or Lexicomp. The FDA-approved formulations are limited to oral tablets (immediate-release and extended-release) and oral suspension 1.
Why This Matters
The absence of IV clarithromycin in U.S. drug databases reflects regulatory reality, not an oversight:
- FDA labeling explicitly states: Clarithromycin is available only as extended-release tablets and oral suspension for administration in the United States 2
- The drug label describes only oral pharmacokinetics and dosing regimens 1
- All CDC and major U.S. guidelines reference only oral clarithromycin formulations 2
International Availability
While IV clarithromycin formulations have existed and been studied in other countries 3, 4, these are not FDA-approved or commercially available in the United States. Historical literature from the 1990s-2000s describes IV clarithromycin use in Europe and other regions 3, 4, but this does not translate to U.S. availability.
Clinical Implications
When IV macrolide therapy is needed in the U.S.:
- Use IV azithromycin as the alternative macrolide with parenteral formulation
- Use IV erythromycin (though less commonly due to tolerability issues)
- Consider sequential IV-to-oral therapy starting with a different IV antibiotic class, then switching to oral clarithromycin once the patient can tolerate oral medications 5
Recent comparative data suggests that when the oral route is not compromised, oral clarithromycin may be equivalent to IV macrolides for moderate-to-severe infections 6, supporting early transition to oral therapy.
Common Pitfall
Do not assume that because a drug exists in IV form internationally, it is available in your local formulary. Always verify FDA approval status and local availability before prescribing.